Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) reported an inducement equity grant made under Nasdaq Listing Rule 5635(c)(4). On July 31, 2026, the company granted 333 restricted stock units (RSUs) to a newly hired employee under its 2022 Inducement Stock Incentive Plan, as amended.

According to Karyopharm, the award is an inducement material to the employee’s acceptance of employment. The RSUs will vest over three years, with 33 1/3% of the shares vesting on each of the three consecutive anniversaries of the grant date, subject to the employee’s continued service with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302841252.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What did Karyopharm Therapeutics (KPTI) announce on August 3, 2026 about inducement grants?

Karyopharm Therapeutics announced an inducement grant of 333 restricted stock units to one newly hired employee. According to Karyopharm, the grant was made on July 31, 2026, under its 2022 Inducement Stock Incentive Plan as an inducement material to the employee’s employment.

How many restricted stock units were granted in Karyopharm Therapeutics’ August 2026 inducement award for KPTI?

Karyopharm Therapeutics granted 333 restricted stock units in the August 2026 inducement award. According to Karyopharm, these RSUs were issued to a single newly hired employee under the 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4) requirements for inducement awards.

What is the vesting schedule for the 333 RSUs granted by Karyopharm Therapeutics (KPTI)?

The 333 RSUs will vest over three years in equal annual installments. According to Karyopharm, 33 1/3% of the shares underlying the RSU award vest on each of the three consecutive anniversaries of the July 31, 2026 grant date, subject to continued service.

Under which plan were the new Karyopharm Therapeutics (KPTI) inducement RSUs granted?

The inducement RSUs were granted under Karyopharm’s 2022 Inducement Stock Incentive Plan, as amended. According to Karyopharm, this plan allows inducement equity awards that are material to a new employee entering employment, consistent with Nasdaq Listing Rule 5635(c)(4) guidelines for such grants.

What conditions apply to vesting of the new Karyopharm Therapeutics (KPTI) inducement RSU grant?

Vesting of the inducement RSUs requires the employee’s continued service with Karyopharm. According to Karyopharm, the RSUs vest over three years only if the individual remains an employee or other service provider through each applicable vesting date, tying the award directly to ongoing service.